CC-93538

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Atopic DermatitisEosinophilic EsophagitisGastroenteritis

508 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

1

Rezzayo

Roche

Phase 3

102

Skyrizi

AbbVie

Phase 3

23

Eucrisa

AAnacor

Phase 3

44

Ciclosporin

Novartis

Phase 3

45

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

66

Adquey

AAcrotech Biopharma Inc.

Phase 3

27

CC-93538

Bristol-Myers Squibb

Phase 3

18

EBGLYSS

Eli Lilly

Preclinical

239

Cibinqo

Pfizer

Preclinical

1110

Prograf

VVeloxis Pharmaceuticals

Preclinical

18Show 17 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Eosinophilic Esophagitis2 trials

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Active, not recruiting·Bristol-Myers Squibb·Phase 3·NCT04991935·368 enrolled

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Completed·Bristol-Myers Squibb·Phase 3·NCT04753697·430 enrolled

Atopic Dermatitis1 trial

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Completed·Bristol-Myers Squibb·Phase 2·NCT04800315·221 enrolled

Gastroenteritis1 trial

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

Completed·Bristol-Myers Squibb·Phase 3·NCT05214768·48 enrolled

Concentration1 trial

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Completed·Bristol-Myers Squibb·Phase 1·NCT04373187·52 enrolled

Unspecified1 trial

Japanese Pharmacokinetic Bridging Study for CC-93538

Completed·Bristol-Myers Squibb·Phase 1·NCT04096105·48 enrolled

Details

Drug Info

Related News